Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807): An Open-Label, Single Arm, Multicenter Phase II Study

Preclinical studies have shown synergism between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and antifolates in solid tumors. This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hong-Yun, Chen, Gong-Yan, Huang, Yan, Li, Xiao-li, Feng, Ji-Feng, Shi, Mei-Qi, Cheng, Ying, Ma, Li-Xia, Zhang, Yi-Ping, Gu, Cui-Ping, Song, Xiang-Qun, Zhou, Da, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602552/
https://www.ncbi.nlm.nih.gov/pubmed/25590835
http://dx.doi.org/10.1097/MD.0000000000000249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602552/
https://www.ncbi.nlm.nih.gov/pubmed/25590835
http://dx.doi.org/10.1097/MD.0000000000000249

Ejemplares similares